StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) stock

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was $13.74B, up 37.4% from the year before. Over ten years it grew 12.8% a year on average. The highest annual figure on record is $13.74B in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.74B+37.4%
FY2024Dec 31, 2024$10.00B+22.1%
FY2023Dec 31, 2023$8.19B+118.1%
FY2022Dec 31, 2022$3.76B+255.8%
FY2021Dec 31, 2021$1.06B-79.5%
FY2020Dec 31, 2020$5.16B+76.5%
FY2019Dec 31, 2019$2.92B-13.7%
FY2018Dec 31, 2018$3.39B-7.9%
FY2017Dec 31, 2017$3.68B-25.0%
FY2016Dec 31, 2016$4.90B+19.2%
FY2015Dec 31, 2015$4.11B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.16B+487.0%
Q2 FY2025Jun 30, 2025$3.51B+211.3%
Q2 FY2024Jun 30, 2024$2.75B+113.9%
Q2 FY2023Jun 30, 2023$2.46B+398.2%
Q2 FY2022Jun 30, 2022$539.00M-29.4%
Q2 FY2021Jun 30, 2021$1.13B+21.8%
Q2 FY2020Jun 30, 2020$1.28B–
Q2 FY2019Jun 30, 2019$493.00M–
Q2 FY2018Jun 30, 2018$763.00M–
Q2 FY2017Jun 30, 2017$925.00M–

More AstraZeneca figures

See a number that looks wrong?